Skip to main content
. 2022 Mar 24;14(7):1641. doi: 10.3390/cancers14071641

Figure 2.

Figure 2

Sankey diagram displaying the proportional flow of patients between first anti-EGFR agent utilized in first- or second-line and anti-EGFR agent chosen for re-exposure.